On 1st December, we implemented changes to the leadership of Cancer Therapeutics CRC that reflect the exciting phase that the CRC is entering. One of the key CRC milestones is to create a legacy organ...
It is with a mix of sadness and gratitude that Cancer Therapeutics CRC (CTx) announces the resignation of Dr George Morstyn from the Board of Directors. George was appointed to the Board in 2008 and s...
The Federal Health Minister, Greg Hunt, announced today, $25M of funding to CTx partner, WEHI, to boost Australia’s capacity to perform compound screening, the first stage along the path of produc...
Cancer Therapeutics CRC (CTx) is pleased to announce the appointment of Dr Brendon Monahan as Chief Scientific Officer. Brendon will succeed Dr Ian Street who was co-founder of CTx in 2007, and who wi...
Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Pfizer w...
Mark is the founder and CEO of Medicines Development for Global Health, a small Melbourne based not-for-profit drug development company. Passionately focused on developing drugs for diseases with high...